| Code | CSB-RA015007MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Divozilimab, targeting MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a B-lymphocyte surface antigen that plays a critical role in B-cell activation, proliferation, and differentiation. This transmembrane protein regulates calcium influx and cell cycle progression in B cells, making it essential for normal B-cell development and immune function. MS4A1 expression is restricted to B cells from the pre-B to mature B-cell stage, and its dysregulation is implicated in various B-cell malignancies including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.
Divozilimab is a therapeutic monoclonal antibody designed to selectively deplete CD20-positive B cells through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity mechanisms. This biosimilar provides researchers with a reliable tool for investigating B-cell biology, studying immune-mediated diseases, evaluating B-cell depletion strategies, and exploring novel therapeutic approaches in oncology and autoimmune research settings.
There are currently no reviews for this product.